Anagenex

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Organon Will Market Lilly’s Emgality, R

The number of biopharmaceutical companies raising venture capital this year has far outpaced the number raising money in public offerings, with 126 venture rounds during the first quarter versus just